Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06385236 · ClinicalTrials.gov registry record · Phase 4
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
A Phase 4 study of Moderate to Severe Asthma, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT06385236 is a Phase 4 study of Moderate to Severe Asthma that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 120 participants, below the 755-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06385236, a Phase 4 study of Moderate to Severe Asthma, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.
Conditions Studied
Interventions
- BIOLOGICAL Dupilumab
- BIOLOGICAL Benralizumab
Study Locations (3)
Arizona
- Mayo Clinic - Scottsdale
California
- University of California, San Diego - La Jolla
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06385236
The ClinicalTrials.gov registry entry for NCT06385236 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 755-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (84% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Dupilumab is the first listed.
NCT06385236 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06385236 about?
NCT06385236 is a clinical study titled "Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping". In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. ...
What is the current status of trial NCT06385236?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-02-19. Estimated completion is 2028-01-31.
What conditions does trial NCT06385236 study?
This clinical trial studies the following conditions: Moderate to Severe Asthma.
What interventions are being tested in trial NCT06385236?
The interventions under investigation include: Dupilumab (BIOLOGICAL), Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06385236?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06385236 being conducted?
This trial has 3 study locations across Arizona, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.